CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Basilea Pharma AG - BSLN CFD

    40.00
    0%
    1.35
    Low: 40
    High: 40.75
    Market Trading Hours* (UTC) Opens on Thursday at 07:00

    Mon - Fri: 07:00 - 15:20

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 1.35
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.015699 %
    Charges from full value of position ($-2.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.015699%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.006523 %
    Charges from full value of position ($-1.24)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.006523%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency CHF
    Margin 5%
    Stock exchange Switzerland
    Commission on trade 0%

    *Information provided by Capital.com

    Basilea Pharmaceutica AG Allschwil ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 40
    Open* 40.05
    1-Year Change* -2.55%
    Day's Range* 40 - 40.75
    52 wk Range 36.80-55.40
    Average Volume (10 days) 20.90K
    Average Volume (3 months) 502.88K
    Market Cap 619.62M
    P/E Ratio 10.05
    Shares Outstanding 11.98M
    Revenue 174.02M
    EPS 4.71
    Dividend (Yield %) N/A
    Beta 1.26
    Next Earnings Date Feb 12, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Oct 3, 2023 40.00 -1.40 -3.38% 41.40 41.80 40.00
    Oct 2, 2023 41.65 -0.05 -0.12% 41.70 42.25 41.10
    Sep 29, 2023 40.00 -0.65 -1.60% 40.65 41.55 40.00
    Sep 28, 2023 40.80 -0.55 -1.33% 41.35 41.40 40.40
    Sep 27, 2023 40.95 0.80 1.99% 40.15 41.10 40.15
    Sep 26, 2023 40.45 -1.25 -3.00% 41.70 41.90 40.45
    Sep 25, 2023 41.45 -0.80 -1.89% 42.25 42.50 41.15
    Sep 22, 2023 42.40 0.20 0.47% 42.20 42.95 42.15
    Sep 21, 2023 42.80 -0.15 -0.35% 42.95 43.60 42.75
    Sep 20, 2023 43.40 -0.05 -0.12% 43.45 43.65 42.90
    Sep 19, 2023 43.15 -0.45 -1.03% 43.60 44.75 43.15
    Sep 18, 2023 43.80 -1.10 -2.45% 44.90 44.95 43.45
    Sep 15, 2023 45.15 -0.20 -0.44% 45.35 45.65 44.60
    Sep 14, 2023 44.80 -1.45 -3.14% 46.25 46.85 44.80
    Sep 13, 2023 46.05 1.00 2.22% 45.05 47.55 44.70
    Sep 12, 2023 47.45 0.60 1.28% 46.85 47.65 46.45
    Sep 11, 2023 46.90 -0.25 -0.53% 47.15 48.30 46.90
    Sep 8, 2023 47.85 0.90 1.92% 46.95 48.00 46.70
    Sep 7, 2023 46.35 0.05 0.11% 46.30 47.20 46.30
    Sep 6, 2023 47.25 0.85 1.83% 46.40 47.30 45.75

    Basilea Pharma AG Events

    Time (UTC) Country Event
    Monday, February 12, 2024

    Time (UTC)

    07:30

    Country

    CH

    Event

    Full Year 2023 Basilea Pharmaceutica AG Earnings Release
    Full Year 2023 Basilea Pharmaceutica AG Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 147.765 148.122 127.629 134.381 132.555
    Revenue 147.765 148.122 127.629 134.381 132.555
    Cost of Revenue, Total 24.603 24.072 24.054 18.868 20.299
    Gross Profit 123.162 124.05 103.575 115.513 112.256
    Total Operating Expense 129.263 147.432 136.165 151.581 156.65
    Selling/General/Admin. Expenses, Total 30.815 29.721 29.422 30.051 31.409
    Research & Development 73.804 93.157 97.41 102.662 104.942
    Operating Income 18.502 0.69 -8.536 -17.2 -24.095
    Interest Income (Expense), Net Non-Operating -9.522 -8.085 -7.485 -6.396 -6.528
    Other, Net 3.122 0.601 1.354 1.214 -0.537
    Net Income Before Taxes 12.102 -6.794 -14.667 -22.382 -31.16
    Net Income After Taxes 12.147 -6.831 -14.722 -22.422 -31.352
    Net Income Before Extra. Items 12.147 -6.831 -14.722 -22.422 -31.352
    Net Income 12.147 -6.831 -14.722 -22.422 -31.352
    Income Available to Common Excl. Extra. Items 12.147 -6.831 -14.722 -22.422 -31.352
    Income Available to Common Incl. Extra. Items 12.147 -6.831 -14.722 -22.422 -31.352
    Diluted Net Income 12.147 -6.831 -14.722 -22.422 -31.352
    Diluted Weighted Average Shares 11.861 11.682 10.2815 10.7557 10.8379
    Diluted EPS Excluding Extraordinary Items 1.02412 -0.58475 -1.43189 -2.08466 -2.89281
    Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
    Diluted Normalized EPS 1.02636 -0.55793 -2.36256 -2.08466 -2.89281
    Unusual Expense (Income) 0.041 0.482 -14.721
    Other Operating Expenses, Total 0
    Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
    Total revenue 84.905 89.118 57.647 93.924 54.198
    Revenue 84.905 89.118 57.647 93.924 54.198
    Cost of Revenue, Total 9.996 9.684 14.919 10.547 13.525
    Gross Profit 74.909 79.434 42.728 83.377 40.673
    Total Operating Expense 48.007 61.531 67.732 77.624 69.808
    Selling/General/Admin. Expenses, Total 16.544 15.194 15.621 15.382 14.339
    Research & Development 21.467 36.656 37.148 51.468 41.689
    Operating Income 36.898 27.587 -10.085 16.3 -15.61
    Interest Income (Expense), Net Non-Operating -5.307 -5.773 -3.749 -4.01 -4.075
    Other, Net 0.276 2.509 1.613 0.793 -0.192
    Net Income Before Taxes 31.867 24.323 -12.221 13.083 -19.877
    Net Income After Taxes 31.84 24.356 -12.209 13.06 -19.891
    Net Income Before Extra. Items 31.84 24.356 -12.209 13.06 -19.891
    Net Income 31.84 24.356 -12.209 13.06 -19.891
    Income Available to Common Excl. Extra. Items 31.84 24.356 -12.209 13.06 -19.891
    Income Available to Common Incl. Extra. Items 31.84 24.356 -12.209 13.06 -19.891
    Diluted Net Income 31.84 24.356 -12.209 13.06 -19.891
    Diluted Weighted Average Shares 11.9781 11.8828 11.8391 11.7986 11.5653
    Diluted EPS Excluding Extraordinary Items 2.65818 2.04969 -1.03124 1.10691 -1.71988
    Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
    Diluted Normalized EPS 2.65818 2.04952 -1.02883 1.12612 -1.70555
    Unusual Expense (Income) 0 -0.003 0.044 0.227 0.255
    Other Operating Expenses, Total 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 175.364 241.066 223.528 184.86 274.738
    Cash and Short Term Investments 84.659 148.7 161.772 129.024 223.034
    Cash 34.7 53.7 50.1 52.5 37.4
    Cash & Equivalents 49.959 0 10.649 56.524 135.634
    Short Term Investments 0 95 101.023 20 50
    Total Receivables, Net 63.612 65.7 37.901 30.315 35.593
    Accounts Receivable - Trade, Net 33.152 8.71 6.242 3.757
    Total Inventory 24.244 22.783 21.192 18.569 14.411
    Other Current Assets, Total 2.849 3.883 2.663 6.952 1.7
    Total Assets 220.848 247.267 229.794 221.467 281.751
    Property/Plant/Equipment, Total - Net 21.571 2.923 5.275 5.162 6.424
    Property/Plant/Equipment, Total - Gross 30.294 17.505 29.348 44.2 45
    Accumulated Depreciation, Total -10.3 -14.6 -24.1 -39 -38.6
    Intangibles, Net 0.578 0.632 0.672 0.372 0.372
    Long Term Investments 0 30 0
    Other Long Term Assets, Total 22.069 0.256 0.319 1.073 0.217
    Total Current Liabilities 74.85 174.408 50.161 75.494 66.684
    Accounts Payable 0.191 10.617 13.151 6.765 6.399
    Accrued Expenses 27.859 33.453 29.052 29.3 26.7
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 9.333 6.833 7.958 39.429 33.585
    Total Liabilities 241.563 305.874 331.84 314.427 348.438
    Total Long Term Debt 131.36 94.544 239.668 197.74 196.982
    Long Term Debt 131.36 94.544 239.668 197.74 196.982
    Other Liabilities, Total 35.353 36.922 42.011 41.193 84.772
    Total Equity -20.715 -58.607 -102.046 -92.96 -66.687
    Common Stock 13.093 12.992 11.922 11.882 11.879
    Retained Earnings (Accumulated Deficit) 26.048 6.577 -33.95 -74.324 -55.05
    Treasury Stock - Common -56.071 -56.559 -52.766 -5.963 -7.235
    Other Equity, Total -3.785 -21.617 -27.252 -24.555 -16.281
    Total Liabilities & Shareholders’ Equity 220.848 247.267 229.794 221.467 281.751
    Total Common Shares Outstanding 11.9513 11.842 10.8673 10.7739 10.7447
    Note Receivable - Long Term 1.266 2.39
    Current Port. of LT Debt/Capital Leases 37.467 123.505
    Dec 2022 Jun 2022 Dec 2021 Jun 2021 Dec 2020
    Total Current Assets 175.364 211.789 241.066 220.189 223.528
    Cash and Short Term Investments 84.659 140.736 148.7 162.849 161.772
    Cash & Equivalents 84.659 45.746 53.7 82.849 60.749
    Short Term Investments 0 94.99 95 80 101.023
    Total Receivables, Net 63.612 39.72 65.7 31.264 37.901
    Accounts Receivable - Trade, Net 33.152 10.946 6.618 8.71
    Total Inventory 24.244 24.754 22.783 20.94 21.192
    Other Current Assets, Total 2.849 6.579 3.883 5.136 2.663
    Total Assets 220.848 236.073 247.267 227.176 229.794
    Property/Plant/Equipment, Total - Net 21.571 21.619 2.923 3.767 5.275
    Property/Plant/Equipment, Total - Gross 30.294 36.044 17.505 20.772 29.348
    Accumulated Depreciation, Total -10.3 -14.4 -14.6 -17 -24.1
    Intangibles, Net 0.578 1.247 0.632 0.467 0.672
    Long Term Investments 0
    Other Long Term Assets, Total 22.069 0.152 0.256 0.363 0.319
    Total Current Liabilities 74.85 155.443 174.408 37.707 50.161
    Accounts Payable 0.191 4.706 10.617 5.378 13.151
    Accrued Expenses 27.859 23.709 33.453 25.235 29.052
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 9.333 9.833 6.833 7.094 7.958
    Total Liabilities 241.563 303.239 305.874 305.928 331.84
    Total Long Term Debt 131.36 94.77 94.544 227.869 239.668
    Long Term Debt 131.36 94.77 94.544 227.869 239.668
    Other Liabilities, Total 35.353 53.026 36.922 40.352 42.011
    Total Equity -20.715 -67.166 -58.607 -78.752 -102.046
    Common Stock 13.093 12.999 12.992 12.931 11.922
    Retained Earnings (Accumulated Deficit) 26.048 -3.794 6.577 -10.401 -33.95
    Treasury Stock - Common -56.071 -55.865 -56.559 -56.309 -52.766
    Other Equity, Total -3.785 -20.506 -21.617 -24.973 -27.252
    Total Liabilities & Shareholders’ Equity 220.848 236.073 247.267 227.176 229.794
    Total Common Shares Outstanding 11.9513 11.8512 11.842 11.7932 10.8673
    Current Port. of LT Debt/Capital Leases 37.467 117.195 123.505
    Note Receivable - Long Term 1.266 1.266 2.39 2.39
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 12.147 -6.831 -14.722 -22.422 -31.352
    Cash From Operating Activities 7.056 -32.02 -54.134 -63.836 -79.21
    Cash From Operating Activities 1.097 0.754 1.19 1.639 1.852
    Non-Cash Items 4.095 5.844 -9.84 3.806 7.009
    Changes in Working Capital -10.283 -31.787 -30.762 -46.859 -56.719
    Cash From Investing Activities 91.649 3.575 -34.963 -0.404 59.391
    Capital Expenditures -3.303 -0.86 -2.265 -0.404 -0.609
    Other Investing Cash Flow Items, Total 94.952 4.435 -32.698 0 60
    Cash From Financing Activities -45.246 16.64 45.067 1.309 -5.986
    Issuance (Retirement) of Stock, Net 4.426 39.852 4.809 1.309 -5.986
    Issuance (Retirement) of Debt, Net -49.672 -23.212 43.451
    Foreign Exchange Effects 0.155 0.501 -0.758 0.067 -1.011
    Net Change in Cash 53.614 -11.304 -44.788 -62.864 -26.816
    Cash Taxes Paid 0.004 0.035 0.026 0.141 0.413
    Cash Interest Paid 6.334 7.074 4.843 5.666 5.795
    Financing Cash Flow Items -3.193
    Dec 2022 Jun 2022 Dec 2021 Jun 2021 Dec 2020
    Net income/Starting Line 12.147 -12.209 -6.831 -19.891 -14.722
    Cash From Operating Activities 7.056 0.149 -32.02 -27.151 -54.134
    Cash From Operating Activities 1.097 0.357 0.754 0.399 1.19
    Non-Cash Items 4.095 2.36 5.844 2.705 -9.84
    Changes in Working Capital -10.283 9.641 -31.787 -10.364 -30.762
    Cash From Investing Activities 91.649 -2.319 3.575 19.113 -34.963
    Capital Expenditures -3.303 -2.329 -0.86 -0.307 -2.265
    Other Investing Cash Flow Items, Total 94.952 0.01 4.435 19.42 -32.698
    Cash From Financing Activities -45.246 -6.764 16.64 26.195 45.067
    Issuance (Retirement) of Stock, Net 4.426 -0.165 39.852 38.82 4.809
    Foreign Exchange Effects 0.155 0.841 0.501 0.249 -0.758
    Net Change in Cash 53.614 -8.093 -11.304 18.406 -44.788
    Financing Cash Flow Items -3.193
    Issuance (Retirement) of Debt, Net -49.672 -6.599 -23.212 -12.625 43.451
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Black Creek Investment Management, Inc. Investment Advisor 5.0663 663670 25430 2023-05-08 LOW
    CI Global Asset Management Investment Advisor/Hedge Fund 4.8722 638240 4613 2022-12-31 MED
    Credit Suisse Asset Management Investment Advisor/Hedge Fund 3.2548 426360 -369 2022-12-31 LOW
    Family (Braginsky) Other Insider Investor 3.0067 393863 5928 2022-12-31 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.7043 354254 2358 2023-07-31 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 2.4333 318750 153618 2022-11-29 LOW
    Zürcher Kantonalbank (Asset Management) Bank and Trust 2.4288 318169 -13081 2023-06-30 LOW
    ACATIS Investment Kapitalverwaltungsgesellschaft GmbH Investment Advisor 2.3711 310600 0 2023-06-30 LOW
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 2.0768 272047 272047 2022-12-31 LOW
    UBS Asset Management (Switzerland) Investment Advisor 1.0368 135818 -1154 2023-07-31 LOW
    JPMorgan Chase & Co Holding Company 1.0318 135155 -267417 2023-03-22 HIGH
    JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 0.8234 107866 0 2023-07-31 LOW
    Saint Olive Gestion Investment Advisor 0.5344 70000 0 2022-12-31 LOW
    Bank J. Safra Sarasin AG (Asset Management) Bank and Trust 0.515 67464 -5901 2023-06-30 MED
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.4538 59446 0 2023-07-31 LOW
    California State Teachers Retirement System Pension Fund 0.3755 49183 723 2022-06-30 LOW
    Baillie Gifford & Co. Investment Advisor 0.2626 34404 1018 2023-04-30 LOW
    Deka Investment GmbH Investment Advisor/Hedge Fund 0.2523 33056 -3500 2022-12-31 LOW
    Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 0.2484 32542 0 2023-04-30 LOW
    BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.2322 30417 190 2023-07-31 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Basilea Company profile

    About Basilea Pharmaceutica AG

    Basilea Pharmaceutica AG is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. It launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Basilea Pharmaceutica AG revenues increased 16% to SF148.1M. Net loss decreased 54% to SF6.8M. Revenues reflect Japan segment increase of 41% to SF56.5M, Republic of Ireland segment increase of 9% to SF62.1M. Lower net loss reflects Research & development expenses, net - B decrease of 4% to SF91.6M (expense), Stock-based Compensation in SGA decrease of 6% to SF1.7M (expense).

    Industry: Biotechnology & Medical Research (NEC)

    Hegenheimermattweg 167b
    ALLSCHWIL
    BASEL-LANDSCHAFT 4123
    CH

    Income Statement

    • Annual
    • Quarterly

    News

    How to Trade The Triple Top

    Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

    14:13, 27 September 2023
    USA flag on the background of stock charts. Financial system in USA

    Q4 lookahead: US indices starting to show signs of trouble?

    US indices start to draw attention as traders focus on the outlook for Q4.

    07:20, 27 September 2023

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    People also watch

    XRP/USD

    0.54 Price
    +2.590% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    US100

    14,794.20 Price
    +1.590% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    BTC/USD

    27,651.25 Price
    +0.590% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    Gold

    1,822.27 Price
    -0.040% 1D Chg, %
    Long position overnight fee -0.0092%
    Short position overnight fee 0.0010%
    Overnight fee time 21:00 (UTC)
    Spread 0.30

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading